The levels of nitric oxide and metabolites in Behçet’ s disease

Amaç: Behçet hastalığının (BH) etiyopatogenezinde endotel hasarı ve fonksiyon bozukluğu suçlanmaktadır. Bu çalışmada vaskülit patogenezinde rolü olduğu bilinen nitrik oksit (NO), asimetrik dimetilarginin (ADMA), simetrik dimetilarginin (SDMA) ve L-Arjinin düzeyleri ile BH aktivitesi arasındaki ilişkinin incelemesi amaçlandı. Yöntem ve gereç: Çalışmaya alınan 60 olgu aktif/inaktif hasta; damar tutulumu açısından da aktif/inaktif ve damar tutulumu olmayan mukokutanöz olarak gruplandırıldı. Nitrit ve nitrat ölçümleri spektrofotometrik; diğer parametreler HPLC cihazında fl orimetrik olarak ölçüldü. Bulgular: Aktif hastaların NO, SDMA, ADMA seviyeleri ile inaktif hastaların SDMA ve ADMA seviyeleri sağlıklı kontrol grubuna göre yüksek bulunurken, incelenen parametreler yönünden aktif /inaktif hasta grupları arasında anlamlı bir fark yoktu. Damar tutulumu aktif grubun SMDA ve ADMA seviyeleri; damar tutulumu inaktif grubun NO, SDMA, ADMA, L-arjinin seviyeleri ile mukokütanöz grubun NO, SMDA, ADMA seviyeleri sağlıklı kontrol grubuna göre anlamlı derecede yüksek bulundu. Ancak, hasta grupları arasında anlamlı bir fark saptanmadı. Sonuç: Çalışmada incelenen parametrelerin, hasta gruplarında sağlıklı kontrol grubuna göre anlamlı düzeyde yüksek olmasına rağmen, hasta grupları arasında anlamlı bir fark olmaması; hastalığın aktivitesini değerlendirmede ve damar tutulumunu göstermede yararlı birer kriter olarak kullanılamayacağı kanaatine varıldı.

Behçet hastalarında nitrik oksit ve metabolitlerinin düzeylerinin araştırılması

Aim: Endothelial damage and dysfunction are held responsible for the etiopathogenesis of Behçet’s disease (BD). In the present study, we aimed to investigate the relationship of BD with nitric oxide (NO), asymmetrical dimethylarginine (ADMA), symmetrical dimethylarginine (SDMA) and L-arginine levels, which are known to play a role in the pathogenesis of vasculitis. Materials and methods: Sixty patients enrolled in the study were allocated to groups as follows: active/inactive patient groups; the patient group with active/inactive vessel involvement, and mucocutaneous patient group without vessel involvement. Results: NO, SDMA, ADMA levels of the active patients and SDMA and ADMA levels of the inactive patients were found to be signifi cantly higher than those of the healthy controls. SMDA and ADMA levels in the group with active vessel involvement; NO, SDMA, ADMA, and L-arginine levels in the group with inactive vessel involvement; and, NO, SDMA, and ADMA levels of the mucocutaneous group were signifi cantly higher than those of the healthy controls. However we detected no statistically signifi cant diff erence among the patient groups. Conclusion: These criteria cannot be utilized in evaluating the activity of the disease and in predicting vessel involvement.

PDF

___

1. Moschella SL, Davis MDP. Neutrophilic Dermatoses. In: Bolognia JL, Jorizzo JL, Rapini RP, editors. Dermatology. 2nd ed. Mosby; 2008. p.379-393.
2. Rizzi R, Bruno S, Dammacco R. Behcet’s disease: an immunemediated vasculitis involving vessels of all sizes. Int J Clin Lab Res 1997; 27: 225-32.
3. Evereklioglu C. Current concepts in the etiology and treatment of Behcet disease. Surv Ophthalmol 2005; 50: 297-350.
4. Düzgün N, Ayaşlıoğlu E, Tutkak H, Şahin M, Aydıntuğ O, Ölmez Ü. Plasma trombomodulin levels in patients with Behçet’s disease. Rheumatol Int 2003; 23: 130-33.
5. Haznedaroğlu İC, Özcebe Öİ, Özdemir O, Çelik İ, Dündar SV, Kirazlı Ş. Impaired haemostatic kinetics and endothelial function in Behçet’s disease. J Intern Med 1996; 240: 181-87.
6. Şahin M, Arslan C, Naziroğlu M, Tunc SE, Demirci M, Sütcü R et al. Asymmetric dimethylarginine and nitric oxide levels as signs of endothelial dysfunction in Behcet’s disease. Ann Clin Lab Sci 2006; 36: 449-54.
7. Ofaz H, Mercanoğlu F, Karaman O. Impaired endotheliumdependent fl ow-mediated dilation in Behcet’s disease: more prominent endothelial dysfunction in patients with vascular involvement. Int J Clin Pract 2005; 59: 777-781.
8. Baatz H, Pleyer U. Modulation of leukocyte-endothelium interaction by nitric oxide synthase inhibitors: eff ects on leukocyte adhesion in endotoxininduced uveitis. Infl amm Res 2001; 50: 534-543.
9. Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005; 46: 518-23.
10. Boger RH, Maas R, Schulze F, Schwedhelm E. Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality. Clin Chem Lab Med 2005; 43: 1124-1129.
11. Boger RH, Bode-Boger SM, Th iele W, Junker W, Alexander K, Frolich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997; 95: 2068-2074.
12. MacAllister RJ, Fickling SA, Whitley GS, Vallance P. Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis. Br J Pharmacol 1994; 112: 43-48.
13. Chambers JC, Haskard DO, Kooner JS. Vascular endothelial function and oxidative stress mechanisms in patients with Behcet’s syndrome. J Am Coll Cardiol 2001; 37: 517–520
14. Evereklioğlu C, Turkoz Y, Er H, Inaloz HS, Ozbek E, Cekmen M. Increased nitric oxide production in patients with Behçet’s disease: Is it a new activity marker? J Am Acad Dermatol 2002; 46: 50-54.
15. Lentz AR, Rodinov RN, Dayal S. Hyperhomocysteinemia, endothelial dysfunction and cardiovascular risk: Th e potential role of ADMA. Atheroscler Suppl 2003; 4: 61-65.
16. International Study Group for Behcet’s Disease. Criteria for diagnosis of. Behcet’s Disease. Lancet 1990; 335: 1078-80.
17. Cortas NK, Wakid NW. Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method. Clin Chem 1990; 36: 1440-1443.
18. Dooley A, Gao B, Bradley N, Abraham DJ, Black CM, Jacobs M, Bruckdorfer KR. Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology, 2006; 45: 676- 684.
19. Motoyama T, Kawano H, Kugiyama K, Hirashima O, Ohgushi M, Tsunoda R et al. Vitamin E administration improves impairment of endothelium-dependent vasodilation in patients with coronary spastic angina. J Am Coll Cardiol 1998; 32: 1672-1679.
20. Şahan F, Özdemir Ş, Karakuzu A, Aktaş A, Kızıltunç A. Behçet hastalığında serum nitrik oksit seviyeleri. T Klin Dermatol 2001; 11: 77-80.
21. Koçak M, Erbaş D, Karabulut AA, Oztürk G, Ekşioğlu M. Behçet’s disease and nitric oxide production. Int J Dermatol 2003; 42: 244-45.
22. Özkan Y, Yardim-Akaydin S, Sepici A, Engin B, Sepici V, Simşek B. Assessment of homocysteine, neopterin and nitric oxide levels in Behçet’s disease. Clin Chem Lab Med 2007; 45: 73-77.
23. Orem A, Vanizor B, Cimşit G, Kiran E, Değer O, Malkoç M. Decreased nitric oxide production in patients with Behçet’s disease. Dermatology 1999; 198: 33-36.
24. Evereklioğlu C, Turkoz Y, Er H, Inaloz HS, Ozbek E, Cekmen M. Increased nitric oxide production in patients with Behçet’s disease: Is it a new activity marker? J Am Acad Dermatol 2002; 46: 50-54.
25. Yıldırım M, Baysal V, Inaloz HS, Doguc D. Th e signifi cance of serum nitric oxide levels in Behçet’s disease and recurrent aphthous stomatitis. J Dermatol 2004; 3: 983-88.
26. Durukan AH, Hürmeriç V, Mumcuoğlu T, Metinyurt G, Özgürtaş T, Bayraktar MZ. Behçet üveit olgularında serum nitrik oksid düzeyi ile üveit aktivitesi arasındaki ilişkinin değerlendirilmesi. Gülhane Tıp Dergisi 2006; 48: 137-41.
27. Ueda S, Yamagishi S, Kaida Y, Okuda S. Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease. Nephrology (Carlton) 2007; 12: 582-90.
28. Böger RH. Th e emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 2003; 59: 824-833.
29. Kielstein JT, Boger RH, Bode-Boger SM, Schaff er J, Barbey M, Koch KM et al. Asymmetric dimethylarginine plasma concentrations diff er in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999; 10: 594-600.
30. Yoshida Y, Yamagishi S, Ueda S, Yoshimura K, Okuda S, Yamakawa R. Aqueous humour levels of asymmetric dimethylarginine (ADMA) are correlated with pigment epithelium-derived factor (PEDF) in patients with Uveitis. J Int Med Res 2007; 35: 892-895.
31. Sugai M, Ohta A, Ogata Y, Nakanishi M, Ueno S, Kawata T, Saito N, Tanaka Y. Asymmetric dimethylarginine (ADMA) in the aqueous humor of diabetic patients. Endocr J 2007; 54: 303-309.
32. Blomster H, Puustjärvi T, Kontkanen M, Valtonen P, Teräsvirta M, Uusitalo H. Asymmetric dimethylarginine is not elevated in exfoliation syndrome but symmetric dimethylarginine is related to exfoliative glaucoma. Graefe’s Arch Clin Exp Ophthalmol 2007; 245: 204-209.
33. Moncada S. Th e L-arjinine: Nitric oxide pathway, cellular transduction and immunological roles. Adv Second Messenger Phosphoprotein Res 1993; 28: 97-99.
34. Blaise GA, Gauvin D, Gangal M, Authier S. Nitric oxide, cell signaling and cell death. Toxicology 2005; 208: 177-192.
35. Uwabo J, Soma M, Nakayama T, Kanmatsuse K. Association of a variable number of tandem repeats in the endothelial constitutive nitric oxide synthase gene with essential hypertension in Japanese. Am J Hypertens 1998; 11: 125-128.